Patient recruitment is complete for a phase 2b clinical trial of Zimura monotherapy for geographic atrophy secondary to dry age-related macular degeneration, Ophthotech announced in a press release.
The randomized, double-masked, sham-controlled, multicenter trial has enrolled 286 patients who will receive various Zimura dosing regimens over 12 months.
Zimura (avacincaptad pegol) is a complement factor C5 inhibitor believed to bind to C5 and stop it from cleaving into terminal fragments C5a and C5b, the release said.
“Recent clinical data together with the preclinical scientific evidence implicating complement in various retinal diseases further invigorates our enthusiasm for the therapeutic potential of Zimura,” Kourous A. Rezaei, MD, Ophthotech chief medical officer, said in the release. “We look forward to initial topline data from this clinical trial, which is expected to be available during the fourth quarter of 2019.”